% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Werner:860824,
      author       = {Werner, Jan-Michael and Schweinsberg, Viola and Schroeter,
                      Michael and von Reutern, Boris and Malter, Michael P. and
                      Schlaak, Max and Fink, Gereon R. and Mauch, Cornelia and
                      Galldiks, Norbert},
      title        = {{S}uccessful {T}reatment of {M}yasthenia {G}ravis
                      {F}ollowing {PD}-1/{CTLA}-4 {C}ombination {C}heckpoint
                      {B}lockade in a {P}atient {W}ith {M}etastatic {M}elanoma},
      journal      = {Frontiers in oncology},
      volume       = {9},
      issn         = {2234-943X},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {FZJ-2019-01479},
      pages        = {84},
      year         = {2019},
      abstract     = {Currently, the blockade of certain immune checkpoints such
                      as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
                      and programmed cell death-1 (PD-1) using checkpoint
                      inhibitors is standard of care in patients with metastatic
                      melanoma, especially with BRAF wild-type. However, several
                      checkpoint inhibitor-related complications have been
                      reported, including severe adverse events in the central and
                      peripheral nervous system. In particular, in the recent
                      past, the occurrence of myasthenia gravis following
                      checkpoint inhibitor monotherapy, particularly nivolumab or
                      ipilimumab, has been reported. In contrast, reports on
                      PD-1/CTLA-4 combination blockade—usually with fatal
                      clinical outcome—are scarce. We here report a case with
                      combination immune checkpoint blockade-related myasthenia
                      gravis with favorable clinical outcome.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000458677200001},
      doi          = {10.3389/fonc.2019.00084},
      url          = {https://juser.fz-juelich.de/record/860824},
}